Organization · Venture Capital
ALSA Ventures
ALSA Ventures is a London-based venture capital firm specializing in early-stage investments in biotechnology companies focused on novel therapeutics. The firm aims to leverage European innovation in life sciences to create impactful businesses.
Overview
What ALSA Ventures does
What ALSA Ventures is
ALSA Ventures is a London-based venture capital firm specializing in early-stage investments in biotechnology companies focused on novel therapeutics. The firm aims to leverage European innovation in life sciences to create impactful businesses.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2019
- Approximate age
- About 7 years
- Structured capabilities
- Funder
- Last reviewed
- April 28, 2026
Official channels
Find ALSA Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
ALSA Ventures as a funder
Investment thesis
ALSA Ventures focuses on leveraging European life sciences innovation to build globally relevant therapeutics companies, investing across the drug development spectrum from discovery to late-preclinical stages.
Focus narrative
ALSA Ventures primarily invests in therapeutics, targeting novel drugs and modalities across various disease areas. Their investment strategy encompasses the entire drug development spectrum, from company formation to syndicate participation with co-investors. The firm is particularly interested in late-preclinical and early-clinical assets, supporting companies that demonstrate breakthrough potential.
Value beyond capital
ALSA Ventures adds value to its portfolio companies through a combination of equity investment and clinical-development support, particularly for late-preclinical therapeutic assets. The firm emphasizes proprietary deal flow, clinical-development experience, and a network of preclinical and clinical experts to enhance the success of its investments.
Terms and economics
- Typical check
- $1,000,000–$5,000,000
- Sweet spot
- $3,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Series A · Series A+ · Series B · Series B+ · Series C · Series C+ · Growth Equity
- Regions
- Europe · Uk · Global
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 7
Portfolio context
Axovia Therapeutics: Developing the first gene therapy for diseases caused by cilia dysfunction. Vantage Biosciences: Addressing vision loss associated with diabetes. Promatix: Creating next-generation cancer therapeutics using multi-omic insights. ReproNovo: A reproductive medicine company that raised $65M in Series A funding. Montis Biosciences: Focused on chronic inflammatory diseases. Epsilogen: Developing IgE antibody-drug therapies for solid tumors. Oxford BioTherapeutics: Utilizing a proprietary target-discovery database for oncology therapeutics.
Common questions
What to know about ALSA Ventures
Upseed classifies ALSA Ventures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 28, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.